Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Cliff Hoyt"'
Autor:
Bernard A Fox, Chichung Wang, Kristin Roman, Carla Coltharp, Carmen Ballesteros-Merino, Shawn M Jensen, Janis M Taube, David L Rimm, Cliff Hoyt, Mei Jiang, Edwin R Parra, Ignacio Wistuba, Elizabeth L Engle, John McGuire, Bethany Remeniuk, Darren Locke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Emerging data suggest predictive biomarkers based on the spatial arrangement of cells or coexpression patterns in tissue sections will play an important role in precision immuno-oncology. Multiplexed immunofluorescence (mIF) is ideally sui
Externí odkaz:
https://doaj.org/article/949449e6557a457d9c3e50a96e2a57b6
Autor:
Cliff Hoyt, Jo Chien, Emma McCune, Scott R. VandenBerg, Tristan Loveday, Jasmine Wong, Michael J. Campbell, Harriet Rothschild, Jennifer Bolen, Laura J. Esserman
Publikováno v:
Cancer Research. 80:P3-09
Background. Ductal carcinoma in situ (DCIS) is a risk factor for the subsequent development of invasive breast cancer. Features of DCIS that are associated with a high risk of a subsequent event include large size (> 5 cm), high grade, comedo necrosi
Autor:
Anna Tsimelzon, Meghana V. Trivedi, Britta Weigelt, Jamunarani Veeraraghavan, Carmine De Angelis, Chandandeep Nagi, Sufeng Mao, Carolina Gutierrez, Cliff Hoyt, Linying Liu, CK Osborne, Antonio C. Wolff, Chichung Wang, Yi Zheng, Anne Pavlick, Tao Wang, Susan G. Hilsenbeck, Kristin Roman, Aleix Prat, Vidyalakshmi Sethunath, Rachel Schiff, Jorge S. Reis-Filho, Paolo Nuciforo, Maria Letizia Cataldo, Mothaffar F. Rimawi
Publikováno v:
Clinical Cancer Research. 26:738-745
Purpose: Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemot
Autor:
Cliff Hoyt, John J. McGuire, Ignacio I. Wistuba, Kristin Roman, Carmen Ballesteros-Merino, Edwin R. Parra, Bethany Remeniuk, David L. Rimm, Chichung Wang, Elizabeth L. Engle, Mei Jiang, Shawn M. Jensen, Darren Locke, Carla Coltharp, Bernard A. Fox, Janis M. Taube
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundEmerging data suggest predictive biomarkers based on the spatial arrangement of cells or coexpression patterns in tissue sections will play an important role in precision immuno-oncology. Multiplexed immunofluorescence (mIF) is ideally suit
Autor:
Cliff Hoyt, Sean Downing, Nikoletta L. Kallinteris, Carmen Ballesteros-Merino, Bernard Fox, Carlo Bifulco, Adam C. Yopp, Brenda S Robertson, Steven King, Joseph S. Shan, Jeffrey J Meyer, Athur Frankel
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Bavituximab is a novel chimeric IgG1 monoclonal antibody targeting the membrane phospholipid, phosphatidylserine (PS), externalized on the luminal surface of endothelium in tumors, tumor cells, and tumor exosomes under stressor cond
Autor:
Linying Liu, Yi Zheng, Cliff Hoyt, Darryn Unfricht, Milind Rajopadhye, Ryan Dilworth, Carla Coltharp, Peter J. Miller
Publikováno v:
Cancer Research. 77:3832-3832
Introduction: Recent insights into the tumor microenvironment have fueled the need for additional information beyond the one or two phenotypes provided by traditional immunohistochemistry (IHC). As a response, manual and automated fluorescent multipl
Autor:
Cliff Hoyt, Nikoletta L. Kallinteris, Rachel E. Sanborn, Joseph S. Shan, Amanda Clement, Leora Horn, Tobias Guennel, Min Tang, David E. Gerber, Ronald B. Natale, Sean Downing
Publikováno v:
Journal of Clinical Oncology. 35:11603-11603
11603 Background: SUNRISE, a global, double-bind, Phase III trial of docetaxel (D) plus bavituximab (B) or D plus placebo (P) in previously treated non-squamous non-small cell lung cancer, demonstrated similar overall survival (OS) in both treatment
Autor:
Cliff Hoyt, Liu Linying, Rena Mao, Carolina Gutierrez, Antonio C. Wolff, C. Kent Osborne, Tao Wang, Chandandeep Nagi, Rachel Schiff, Susan G. Hilsenbeck, Yi Zheng, Carmine De Angelis, Mothaffar F. Rimawi, Kristin Roman, Chichung Wang
Publikováno v:
Journal of Clinical Oncology. 34:608-608
608Background: Dual HER2 blockade with LT without chemotherapy resulted in a substantial pathologic complete response (pCR) rate in HER2+ BC patients (pts) (TBCRC006). High levels of tumor infiltrating lymphocytes (TILs) at diagnosis have shown to be
Publikováno v:
The FASEB Journal. 21
Publikováno v:
Cancer Research. 75:2347-2347
Background: The presence of high levels of tumor-infiltrating lymphocytes (TILs) is associated with favorable outcome in diverse human neoplasms including non-small cell lung cancer (NSCLC). Previous studies suggest that different TIL subtypes have d